Drug Trial Radar · NCT01379625
Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder
Last checked: Nov 20, 2026Latest source record: Mar 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Sep 2011
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Lead sponsor
- Oregon Health and Science UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Pittsburgh
- First posted
- Jun 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Humans eat long-chain fat in their diet and use it for energy during exercise and during periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use dietary fat for energy. They sometimes develop muscle breakdown, and severe pain with exercise or illness. They can also develop a heart that does not function properly. These patients are tired and expend less energy than people who do not have a long-chain fatty acid oxidation disorder. However, they can use a supplement oil called medium chain triglyceride or MCT. This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders. Funding source - FDA's OOPD
Conditions
- Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency
- Carnitine Palmitoyltransferase 2 (CPT2) Deficiency
- Mitochondrial Trifunctional Protein (TFP) Deficiency
- Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency
Interventions
TriheptanoinDrug
Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Energy ExpenditureTime frame: change from baseline after 4 months of treatment
- Ejection FractionTime frame: 4 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Oregon Health & Science University
Portland, Oregon
University of Pittsburgh
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.